Value20202021202220232024TTMSelling/general/admin expenses4.23 M5.94 M15.66 M9.09 M6.46 M7.17 MResearch & development10.23 M20.99 M27.64 M8.97 M6.32 M5.85 MOperating income11.76 M24.22 M40.6 M15.77 M12.78 M13.01 MNon-Operating Income, Total792 K179 K1.55 M22.89 M2.29 M72.66 MInterest expense, net of interest capitalized———2.04 M853 K0Non-Operating Income, excl. Interest Expenses546 K187 K1.55 M01.43 M69.05 MUnusual income/expense246 K-8 000—20.86 M4 359—Pretax income11.51 M22.99 M37.66 M5.09 M15.92 M75.31 MEquity in earnings——————Taxes00100 K03.18 M11.94 MNon-controlling/minority interest—20.74 M1.2 M437 K43 K44 KAfter tax other income/expense——————Net income before discontinued operations11.51 M22.99 M36.56 M5.53 M19.1 M64.27 MDiscontinued operations——————Net income11.51 M22.99 M36.56 M5.53 M19.1 M64.27 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders11.51 M22.99 M36.56 M5.53 M19.1 M64.27 MBasic earnings per share (Basic EPS)——0.940.14-0.481.04Diluted earnings per share (Diluted EPS)——0.940.14-0.481Average basic shares outstanding——39 M40.32 M40.83 M165.12 MDiluted shares outstanding——39 M40.57 M40.83 M167.91 MEBITDA-1.51 M—————EBIT-1.52 M—————Cost of revenue0—————Other cost of goods sold——————Depreciation & amortization (cash flow)7 00077 K58 K196 K193 K122 K
Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.